Connect with us

BIOTECH

Premier Biomedical Inc (OTCMKTS:BIEI) Searches For Development Partner To Develop Patent Pending Technology

Published

on

Premier Biomedical Inc (OTCMKTS:BIEI) reported that they are actively looking for an associate to advance their patented extracorporeal treatment procedure in together with their patent pending process for treating ailments through the application of lasers.

The buzz

The methodology uses the concept of curing the blood outside the human body in a continuous flow procedure, together with an emissive energy means, such as a laser, to destroy directed antigens in the blood, before returning the blood to the person. The firm has exceptional privileges to three dispensed patents, one provisional patent application and six pending applications, all related to unique treatments for cancer as well as extracorporeal treatments for different life-threatening ailments.

Dr. Felder, the Inventor of the underlying technologies, expressed that the application of lasers in conjunction with their extracorporeal treatment procedure is a thrilling concept, as it should eliminate any infectious ailment, without the probability of pathogen resistance, or the action of side effects from the therapy. It also has the prospect for being an efficacious and inexpensive treatment for septicemia — a major cause of death globally.

William A. Hartman, the CEO and President of Premier Biomedical, expressed that they consider this combination of their patented extracorporeal treatment procedure with their patent awaiting emissive energy ablation of directed antigens could pave a complete new chapter in the means diseases are cured. The efficacy and safety of treatment protocols for a broad range of ailments could be considerably improved.

Premier Biomedical marks as a research-based publicly traded firm that plans to develop and discover medical treatments for a broad range of ailments in humans. The company has obtained, through different license agreements, the know-how behind three allowed US Patents, several pending provisional patents, as well as a ‘PCT’ Europe National Patent. Premier Biomedical was established back in 2010.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.